Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

90.64 +3.43 (+3.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
Via Benzinga
News headline image
Rhythm Pharma's Setmelanotide Shows Encouraging Action In Hypothalamic Obesity Study ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Rhythm Pharmaceuticals ↗
Rhythm Pharmaceuticals (NASDAQ:RYTM) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Rhythm Pharma Secures Non-Dilutive Financing Of $100M To Use Of This... ↗
 
Via Benzinga
News headline image
Expert Ratings for Rhythm Pharmaceuticals ↗
Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter: 
Via Benzinga
News headline image
Crude Oil Prices Fall Sharply; Greenwich LifeSciences Shares Spike Higher ↗
U.S. stocks traded mixed toward the end of trading after recording losses in the previous session. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
  
Via Benzinga
News headline image
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Rhythm Shares Climb Following Positive Interim Results From Mid-Stage Obesity Study ↗
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced positive interim results from a Phase 2 clinical trial evaluating setmelanotide for the treatment of severe obesity and hyperphagia in people living with... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
News headline image
33 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
U.S. Markets Open Higher; Dow Rises Around 200 Points ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Friday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Good morning! We're entering the final day of trading for the week with a look at the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
21 Stocks Moving in Friday's Pre-Market Session ↗
Gainers Athersys, Inc. (NASDAQ: ATHX) rose 48.5% to $0.4755 in pre-market trading after dropping more than 12% on Thursday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 34.4% to $2.81 during Thursday's after-market session. The market value of their outstanding shares is at $29.0 million. 
Via Benzinga
News headline image
Rhythm Pharmaceuticals' Shares Dive Following FDA's Verdict On IMCIVREE Drug ↗
The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ (NASDAQ: RYTM) supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R)... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
27 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
93 Biggest Movers From Yesterday ↗
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
News headline image
70 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
News headline image
5 Biotech Stocks To Watch During The Week Of June 13 ↗
Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a... 
Via Benzinga
News headline image
30 Stocks Moving in Monday's Pre-Market Session ↗
Gainers G Medical Innovations Holdings Ltd (NASDAQ: GMVD) rose 53.6% to $0.5301 in pre-market trading after dropping more than 28% on Friday. 
Via Benzinga
News headline image
6 Biotech Stocks to Buy Now Ahead of These June Catalysts ↗
These biotech stocks face some key make-or-break events in June that could have big implication for their futures. 
Via InvestorPlace
News headline image
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
News headline image
3 Stocks to Buy the Dip Now ↗
You've heard the adage "buy the dip," but not all dips are made equal. There are several strategies for finding worthwhile discounted stocks. 
Via InvestorPlace
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
During Thursday, 351 stocks hit new 52-week lows. 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.